Edgar Filing: Pinkas Alon - Form 4

Pinkas Alon Form 4							
Check this box	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES					PPROVAL 3235-0287 January 31,	
Section 16. Form 4 or Form 5 Filed pure						Expires: 200 Estimated average burden hours per response 0.	
(Print or Type Responses)							
1. Name and Address of Reporting I Pinkas Alon	Symbol BRAIN	er Name and Ticker or T ISTORM CELL APEUTICS INC. [B	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (M C/O BRAINSTORM CELL THERAPEUTICS, INC., 605 THIRD AVENUE, 34TH FLO	(Month/ 08/01/2	of Earliest Transaction Day/Year) 2012		X Director Officer (giv below)		% Owner er (specify	
(Street) NEW YORK, NY 10158		Filed(Month/Day/Year) Applicable Lin _X_ Form filed			r Joint/Group Filing(Check by One Reporting Person y More than One Reporting		
(City) (State)	(Zip) Tab	le I - Non-Derivative S	ecurities Ac	quired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)2. Transaction Date (Month/Day/Year)			A) or S f (D) 1 and 5) 0 (A) 7 or 6	5. Amount of Securities Beneficially Owned Following Reported Fransaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Report on a separate line	for each class of sec	·	D) Price				

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Pinkas Alon - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount Underlying Securitie (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amou Numb Shares
Stock Option (right to buy)	\$ 0.15	08/01/2012		А	130,000	09/01/2012 <u>(1)</u>	08/01/2022	Common Stock	130,0

Reporting Owners

Reporting Owner Name / Address		Relationships				
	Director	10% Owner	Officer	Other		
Pinkas Alon C/O BRAINSTORM CELL THERAPEUTICS, INC. 605 THIRD AVENUE, 34TH FLOOR NEW YORK, NY 10158	Х					
Signatures						
/s/ Thomas B. Rosedale (Pursuant to Power of Attorney)	09/06/2012					
**Signature of Reporting Person		Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on September 1, 2012 until fully vested
 (1) and exercisable on the first anniversary of the date of grant, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.